INNOSCIENCE (Suzhou) Technology Holding Co., Ltd. has released a comprehensive corporate governance update covering four key areas: amendments to its Articles of Association, board re-election, senior-management appointments and a revised share structure following large-scale domestic-to-H-share conversion. All resolutions are subject to approval at the forthcoming extraordinary general meeting (EGM).

Share Capital Realignment • Following the June 2026 conversion of 373.84 million domestic shares into H-shares, issued capital remains 915.10 million ordinary shares; however, the free-float mix has shifted markedly. Domestic unlisted shares fall from 389.56 million (42.57%) to 15.72 million (1.72%), while H-shares rise to 899.38 million (98.28%). • Article 3 of the Articles of Association will be updated to reflect the new capital structure.

Governance Amendments • Planned revisions expand shareholder meeting powers to include equity incentive and employee stock ownership plans, require independent directors to present annual performance reports, and introduce special-resolution status for equity incentive schemes. • Board size will reduce from 11 to 9 directors, comprising 3 executive, 2 non-executive, 3 independent non-executive and 1 employee representative director.

Board Re-election (Three-Year Term) Executive Director nominees: – Dr. Weiwei Luo (founder & chair). Estimated FY 2026 remuneration: RMB4.61 million (70.6% salary, 29.4% bonus). – Dr. Wu Jingang (CEO). Estimated FY 2026 remuneration: RMB7.00 million (57.1% salary, 42.9% bonus). – Mr. Jay Hyung Son. Estimated FY 2026 remuneration: RMB2.00 million (salary only).

Non-Executive Director nominees: Dr. Wang Can and Ms. Zhang Yanhong (no remuneration).

Independent Non-Executive Director nominees: Mr. Wong Hin Wing, Dr. Yi Jiming and Dr. Simon Shi-Ning Yang. Monthly allowance: RMB40,000 (before tax). All three affirm compliance with HKEX Rule 3.13 independence criteria.

Departing Directors Mr. Zhong Shan (executive director & CFO), Ms. Cui Mizi (non-executive director) and Dr. Philip Ching Ho Chan (independent non-executive director) will step down upon completion of the re-election process.

Chief Executive Officer Dr. Wu Jingang is reappointed CEO for a new three-year term effective 28 August 2026, concurrent with his board duties.

Chief Financial Officer Transition Ms. Wei Yu becomes CFO for a three-year term from 28 August 2026, succeeding Mr. Zhong Shan. Ms. Yu brings 22 years of capital-market and strategic-finance experience, most recently as CFO of Shanghai AutoFlight. Mr. Zhong departs without disagreement with the board.

Next Steps The EGM date and circular—detailing the proposed amendments and director slate—will be issued in due course. Pending shareholder consent and regulatory filings, the updated Articles of Association and leadership changes will take effect immediately after the meeting.